1-Aminobenzotriazole (ABT) (Synonyms: ABT, 3-Aminobenzotriazole, 1-Benzotriazolylamine, NSC 114498, NSC 656987) |
Catalog No.GC14781
One-Click Copy Product Info
|
1-Aminobenzotriazole (ABT) is an orally active nonspecific and irreversible inhibitor of cytochrome P450 (CYP).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1614-12-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
1-Aminobenzotriazole (ABT) is an orally active nonspecific and irreversible inhibitor of cytochrome P450 (CYP)[1]. 1-Aminobenzotriazole is a substrate and inhibitor of N-acetyltransferase (NAT)[2].
In vitro, 1-Aminobenzotriazole (1mM) treatment of sandwich cultured human hepatocytes (SCHH) for 0-60min significantly inhibited the intracellular activities of CYP3A, CYP2C9, CYP2D6 and CYP1A2. The residual activity of CYP3A was 3% of the control, while the residual activities of CYP2C9, CYP2D6 and CYP1A2 remained between 5% and 35%[3].
In vivo, oral administration of 1-Aminobenzotriazole (0, 50, 100, 200, 300mg/kg) to SD rats significantly inhibited the hepatic metabolism of MDZ, but could not completely inhibit the formation of 1'-OH MDZ[4]. Oral administration of 1-Aminobenzotriazole (50mg/kg) to male mice for 3 days suppressed the dominant lethal effect of acrylamide-induced spermatocytes[5]. Treatment of rats with 1-Aminobenzotriazole (78mg/kg) increased organ weights and mortality, and increased sensitivity to inflammation-induced multiple organ failure (MOF)[6].
References:
[1] de Montellano P R O. 1-Aminobenzotriazole: a mechanism-based cytochrome P450 inhibitor and probe of cytochrome P450 biology[J]. Medicinal chemistry, 2018, 8(3).
[2] Sun Q, Harper T W, Dierks E A, et al. 1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase[J]. Drug metabolism and disposition, 2011, 39(9): 1674-1679.
[3] Kimoto E, Walsky R, Zhang H, et al. Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes[J]. Drug Metabolism and Disposition, 2012, 40(2): 407-411.
[4] Parrish K E, Mao J, Chen J, et al. In vitro and in vivo characterization of CYP inhibition by 1‐aminobenzotriazole in rats[J]. Biopharmaceutics & drug disposition, 2016, 37(4): 200-211.
[5] Adler I D, Baumgartner A, Gonda H, et al. 1-Aminobenzotriazole inhibits acrylamide-induced dominant lethal effects in spermatids of male mice[J]. Mutagenesis, 2000, 15(2): 133-136.
[6] Carcillo J, Kost C, Korzekwa K, et al. 1-aminobenzotriazole (ABT), the cytochrome P450 suicide inhibitor, sensitizes rats to zymosan induced-multiple organ failure184[J]. Pediatric Research, 1998, 43(4): 34-34.
| Cell experiment [1]: | |
|
Cell lines |
Sandwich-cultured human hepatocytes (SCHH) |
|
Preparation Method |
After preincubation of Sandwich-cultured human hepatocytes (SCHH) with 1-Aminobenzotriazole (1mM) for 0-60min. CYP1A2, CYP2C9, CYP2D6, and CYP3A probe substrate mix was added to SCHH and incubated for an additional 30min. |
|
Reaction Conditions |
1mM; 0-60min |
|
Applications |
Intracellular hydroxymidazolam formation, used as a marker of CYP3A activity, was essentially eliminated by preincubation with ABT (3% of control). Residual activities of CYP2C9, CYP2D6, and CYP1A2 remained between 5% and 35% in the presence of 1-Aminobenzotriazole preincubation for up to 60min. |
| Animal experiment [2]: | |
|
Animal models |
Male Sprague-Dawley rats |
|
Preparation Method |
Rats were orally administered 0, 50, 100, 200, 300mg/kg of 1-Aminobenzotriazole (dissolved in water) 2h before oral (2mg/kg) or intravenous (1mg/kg) midazolam(MDZ). Rats were fasted for 12h before 1-Aminobenzotriazole administration, and blood was collected from the jugular vein at 10 time points (0.083, 0.25, 0.5, 1, 2, 4, 8, 12, 24, and 36h) after MDZ administration using sodium/potassium EDTA as an anticoagulant. Plasma samples were analyzed by LC-MS/MS. |
|
Dosage form |
0, 50, 100, 200, 300mg/kg; p.o. |
|
Applications |
1-Aminobenzotriazole can significantly inhibit the oxidative metabolism of MDZ, but cannot completely inhibit the formation of 1'-OH MDZ. |
|
References: [1]Kimoto E, Walsky R, Zhang H, et al. Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes[J]. Drug Metabolism and Disposition, 2012, 40(2): 407-411. [2]Parrish K E, Mao J, Chen J, et al. In vitro and in vivo characterization of CYP inhibition by 1‐aminobenzotriazole in rats[J]. Biopharmaceutics & drug disposition, 2016, 37(4): 200-211. |
|
| Cas No. | 1614-12-6 | SDF | |
| Synonyms | ABT, 3-Aminobenzotriazole, 1-Benzotriazolylamine, NSC 114498, NSC 656987 | ||
| Chemical Name | 1H-benzo[d][1,2,3]triazol-1-amine | ||
| Canonical SMILES | NN1N=NC2=CC=CC=C12 | ||
| Formula | C6H6N4 | M.Wt | 134.14 |
| Solubility | ≥ 6.7mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 7.4549 mL | 37.2745 mL | 74.549 mL |
| 5 mM | 1.491 mL | 7.4549 mL | 14.9098 mL |
| 10 mM | 745.5 μL | 3.7274 mL | 7.4549 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >97.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)